Biomarkers · Inflammation
Interleukin-8 (IL-8)
Lower values go with lower risk of death. Not measured in our NHANES panel. The curve is drawn from the published study (source below).
IL-8 and risk of death
Published curve higher than the NHANES fitNHANES fit higher
Risk of death relative to the curve's reference value, drawn from the published study (source below).
IL-8 by age and sex
Each bar runs from the 5th to the 95th percentile, the darker part from the 25th to the 75th, and the tick is the median. Not a reference range or a target.
The percentiles as a table
| Sex | Age | 5th | 25th | Median | 75th | 95th | n | Cycle / source |
|---|---|---|---|---|---|---|---|---|
| All | 40-59 | 5.81 | 8.92 | 12.3 | 16.5 | 25.3 | 349 | MIDUS 3 Biomarker Proj… |
| All | 60+ | 6.86 | 9.71 | 13.3 | 17.2 | 33.6 | 389 | MIDUS 3 Biomarker Proj… |
| All | all | 6.04 | 9.31 | 12.9 | 16.9 | 28.7 | 738 | MIDUS 3 Biomarker Proj… |
| Men | 40-59 | 5.74 | 8.54 | 11.8 | 16.3 | 25.2 | 133 | MIDUS 3 Biomarker Proj… |
| Men | 60+ | 6.87 | 9.45 | 13.2 | 16.1 | 29.6 | 193 | MIDUS 3 Biomarker Proj… |
| Men | all | 6.08 | 8.95 | 12.5 | 16.1 | 28.4 | 326 | MIDUS 3 Biomarker Proj… |
| Women | 40-59 | 5.95 | 9.17 | 12.5 | 16.6 | 25.1 | 216 | MIDUS 3 Biomarker Proj… |
| Women | 60+ | 6.88 | 10.1 | 13.3 | 18.4 | 35.5 | 196 | MIDUS 3 Biomarker Proj… |
| Women | all | 6.04 | 9.67 | 12.9 | 17.3 | 28.7 | 412 | MIDUS 3 Biomarker Proj… |
What studies found when this marker was changed
They describe what happened in those study groups, not a recommendation. See all catalogued interventions.
Measured changes in IL-8, study by study
2 effects with a numeric size, each from one study arm: the dot is the reported change, the line its 95% interval where one was given. Green points move the marker the way lower risk of death lies; amber the other way. Study results in the groups studied, not predictions for a person.
| Type | Intervention | Reported effect | Evidence | Source |
|---|---|---|---|---|
| supplement | Oral nicotinamide riboside for 6 weeks in patients with stable COPD, with follow-up 12 weeks after stopping | Sputum IL-8 52.6% lower (95% CI 7.6-75.7%) than placebo at 6 weeks, persisting 12 weeks after treatment (-63.7%) | RCT | Norheim KL, Ben Ezra M, Heckenbach I, et al. Effect of nicotinamide riboside on… |
Things that worsen it
| Type | Condition or exposure | Reported effect | Evidence | Source |
|---|---|---|---|---|
| supplement | Twelve weeks of a 16-strain Lactobacillus and Bifidobacterium probiotic in children with autism spectrum disorder | Plasma IL-8 rose by 66.6 pg/mL (P=0.035) with probiotics; MIP-1beta +74.5 pg/mL; IFN-gamma fell | RCT | Naranjo-Galvis CA, Trejos-Gallego DM, Correa-Salazar C, et al… |
What else moves this marker
They describe those study groups, not an individual, and an association is not a cause.
Diseases and conditions
| What | Effect on the marker | Comparison · population | Source |
|---|---|---|---|
| ↑ Hepatocellular carcinoma · HCC patients vs controls (CXCL8) | SMD +1.81 | HCC patients vs controls · 65 studies; 5828 HCC patients vs 4909 controls (chemokines in blood or tissue) | meta analysis · PMID 33300549 |
Sources
- Risk curve: Moreno Velásquez I 2015 (PMID 25302539): all-cause HR 1.12 (1.02-1.23) per SD increment in log-transformed IL-8. Scaled to US values (NHANES).
- Moreno Velásquez I, Ärnlöv J, Leander K, Lind L, Gigante B, Carlsson AC. Interleukin-8 is associated with increased total mortality in women but not in men-findings from a community-based cohort of elderly. Ann Med. 2015;47(1):28-33.
Map Interleukin-8 (IL-8) against another biomarker.
Related markers: Alpha-1-Antichymotrypsin (AACT) · Alpha-1-Antitrypsin (AAT) · Antinuclear Antibodies (ANA) · CD4:CD8 T-Cell Ratio · CD8+ T-Cell Count · Erythrocyte Sedimentation Rate (ESR) · Fibrinogen · Growth Differentiation Factor-15 (GDF-15)